Optic neuritis and demyelination
Optic neuritis is the commonest acute optic nerve disease of young adults and is often the first sign of multiple sclerosis. This lesson covers the typical attack, what the Optic Neuritis Treatment Trial showed about steroids and the risk of multiple sclerosis, and the atypical features that point to neuromyelitis optica spectrum disorder or MOG antibody disease, where the treatment and the outlook are different.
What optic neuritis is
Optic neuritis is inflammation of the optic nerve. In the UK the usual cause is demyelination: an immune attack that strips the myelin sheath from the nerve fibres. The optic nerve is a tract of the central nervous system, and its myelin is made by oligodendrocytes, the same cells that myelinate the brain and spinal cord. That is why the disease that most often damages it is multiple sclerosis (MS), and why optic neuritis may be the first event of MS. Up to three quarters of people with MS have at least one attack of optic neuritis in their lifetime.
Myelin allows fast conduction by letting the impulse jump from node to node. A demyelinated segment conducts slowly or not at all, so vision falls. When inflammation settles, conduction returns, partly through remyelination and partly through redistribution of ion channels along the bare axon. This explains the two central facts of the typical attack: vision drops over days, and then recovers over weeks even without treatment.
The typical attack
The typical patient is a young adult, more often a woman, with loss of vision in one eye that worsens over several days and reaches its worst at about two weeks. Pain on eye movement is present in about nine in ten patients and may come before the visual loss. The pain arises because the swollen nerve sheath is pulled on by the rectus muscles, which attach around it at the orbital apex.
- Reduced acuity, anywhere from slight blur to no perception of light.
- Reduced colour vision, often out of proportion to acuity. Reds look washed out (red desaturation).
- A relative afferent pupillary defect in the affected eye.
- A visual field defect, classically a central scotoma, although any pattern can occur.
- A normal optic disc in about two thirds of cases, because the inflammation lies behind the eye (retrobulbar neuritis). The disc is swollen in about one third (papillitis).
Two named phenomena are common after recovery. In the Uhthoff phenomenon, vision blurs temporarily when body temperature rises, for example during exercise or a hot bath, because heat blocks conduction in partly demyelinated fibres. In the Pulfrich phenomenon, an object moving from side to side seems to move in an ellipse, because the signal from the affected eye arrives late. The same delay is what the visual evoked potential measures: the cortical response to a pattern stimulus is delayed, and it often stays delayed after vision has recovered.
Weeks later the disc becomes pale, most obviously on the temporal side, and optical coherence tomography shows thinning of the nerve fibre and ganglion cell layers.
The Optic Neuritis Treatment Trial
The Optic Neuritis Treatment Trial (ONTT) is the trial every candidate should know. It randomised 457 adults with acute optic neuritis to one of three arms: intravenous methylprednisolone for three days followed by a short course of oral prednisolone, oral prednisolone alone at 1 mg/kg/day, or oral placebo. (The trial used prednisone, the American equivalent of prednisolone.)
- Intravenous steroid speeded recovery but made no difference to final vision. At six months the groups were the same.
- Oral prednisolone alone at the standard dose gave no visual benefit and was followed by a higher rate of recurrence of optic neuritis than either other arm. It is therefore not used.
- Intravenous steroid roughly halved the rate of definite MS over the first two years (7.5% against 16.7% with placebo), but the effect faded after that and the long-term risk of MS was unchanged.
- The outlook is good whatever is done: 94% of patients had 6/12 or better at five years, and only 3% had 6/60 or worse.
- Recovery usually starts within a few weeks and can continue for up to a year.
In practice, a typical attack needs no treatment for the sake of vision. High-dose methylprednisolone is offered when faster recovery matters: severe pain, poor vision in the other eye, or bilateral loss. The steroid dose used was 1 g of intravenous methylprednisolone daily for three days. High-dose oral methylprednisolone is used as an alternative in many units.
The risk of multiple sclerosis and the role of MRI
The most useful investigation after a first attack is MRI of the brain and orbits with gadolinium contrast. In the orbit it shows a bright, enhancing segment of optic nerve, usually short. In the brain it looks for white matter lesions typical of demyelination, which lie around the ventricles, next to the cortex, in the brainstem and cerebellum, and in the spinal cord.
The ONTT followed its patients for fifteen years. Overall, half developed MS. The baseline brain MRI divided them sharply.
| Baseline brain MRI | Risk of MS at 15 years |
|---|---|
| No white matter lesions | 25% |
| One or more lesions | 72% |
| All patients | 50% |
An abnormal scan is therefore the main reason for referral to neurology. MS is diagnosed when lesions are shown to be spread in both space and time, and a scan can sometimes show both at the first attack. Disease-modifying treatment for MS is a matter for neurologists and is outside this lesson.
Atypical optic neuritis: when to think again
The typical attack is so consistent that departures from it carry meaning. The following features should prompt blood tests for specific antibodies and a search for other causes such as sarcoidosis, syphilis, lupus and compressive or ischaemic disease.
- Both eyes affected at once or in quick succession.
- Very severe loss with poor or no recovery, or vision still falling after two weeks.
- No pain, or severe pain that persists.
- Marked disc swelling, haemorrhages or a macular star.
- Age outside the usual young adult range.
- Relapse when steroids are reduced.
- Other symptoms: weakness or numbness of the legs, bladder disturbance, or unexplained hiccups and vomiting.
Neuromyelitis optica spectrum disorder (NMOSD) is caused by an IgG antibody against aquaporin-4, a water channel on astrocytes. The target is the astrocyte, not myelin, and the damage is more destructive. Aquaporin-4 is concentrated in the optic nerves, the spinal cord and the area postrema of the medulla, which explains the three core syndromes: severe optic neuritis, longitudinally extensive transverse myelitis (a cord lesion spanning three or more vertebral segments), and the area postrema syndrome of intractable hiccups, nausea and vomiting. The optic neuritis is often bilateral, tends to involve a long length of the nerve reaching back to the chiasm, and recovers poorly. Many patients are left with 6/60 or worse in an affected eye. NMOSD is commoner in women and in people of African and Asian ancestry.
MOG antibody disease (MOGAD) is caused by antibodies to myelin oligodendrocyte glycoprotein, a protein on the outer surface of myelin. Optic neuritis is its commonest presentation in adults. It is often bilateral, with marked disc swelling in most patients, and MRI shows a long segment of anterior nerve with enhancement spreading to the nerve sheath and surrounding fat. Vision may fall very low but usually responds quickly to steroids, and attacks tend to relapse as the steroid is withdrawn. Young children with MOG antibodies more often present with acute disseminated encephalomyelitis.
| MS-related (typical) | NMOSD | MOG antibody disease | |
|---|---|---|---|
| Antibody | None | Aquaporin-4 IgG | MOG IgG |
| Eyes | One | One or both | Often both |
| Disc | Normal in two thirds | Normal or swollen | Usually markedly swollen |
| MRI of the nerve | Short segment | Long, posterior, may reach chiasm | Long, anterior, sheath enhancement |
| Severity at worst | Moderate | Severe | Severe |
| Recovery | Good | Poor without urgent treatment | Good, but relapses and steroid dependence |
Treatment of the antibody diseases
Unlike typical optic neuritis, attacks of NMOSD are treated urgently, because each attack can leave permanent damage. High-dose intravenous methylprednisolone is given at once, and plasma exchange is added early if recovery is poor. Long-term immunosuppression is then needed to prevent relapse. The choice of agent, including antibody treatments directed at B cells and complement, is made by a specialist neurology service.
MOG antibody disease is also treated with high-dose steroid, followed by a slow oral taper because early withdrawal invites relapse. Some patients have only one attack, and others need longer-term treatment. Getting the diagnosis right matters for another reason: the antibody diseases are not MS, and their long-term management is different.
Summary
- Typical optic neuritis is unilateral, painful on eye movement, worsens over days to about two weeks and then recovers.
- Signs are reduced acuity and colour vision, an RAPD, a central scotoma and a disc that is normal in about two thirds of cases.
- ONTT: intravenous methylprednisolone speeds recovery but does not change final vision.
- ONTT: oral prednisolone alone at 1 mg/kg/day increased recurrences and should not be used.
- At five years, 94% of ONTT patients saw 6/12 or better.
- MS risk at 15 years was 50% overall: 25% with a normal baseline brain MRI and 72% with one or more lesions.
- Uhthoff phenomenon is blurring with heat or exercise; Pulfrich phenomenon is altered perception of motion in depth.
- Bilateral, severe, painless, poorly recovering or steroid-dependent optic neuritis is atypical and needs aquaporin-4 and MOG antibody tests.
- NMOSD (aquaporin-4 antibody) causes severe optic neuritis, long cord lesions and area postrema syndrome, and attacks need urgent steroid and plasma exchange.
- MOG antibody optic neuritis is often bilateral with marked disc swelling, responds well to steroid and tends to relapse.
Check yourself
Quick recall on this lesson. These are easier than the question bank.
Written for revision. It is not a source of clinical advice, and guidance changes.